Search

Introduction: Guselkumab is a human monoclonal antibody against IL-23 used in the treatment of moderate-to-severe psoriasis. This post-hoc analysis evaluated the efficacy and safety of guselkumab in the Asian subpopulation of VOYAGE 1 and VOYAGE 2 through 5 years. Methods: The proportions of guselkumab-treated Asian patients (VOYAGE 1 and 2) achieving Psoriasis Area and Severity Index (PASI) 90 and PASI 100, Investigator's Global Assessment (IGA) scores of 0/1 and 0, and Dermatology Life Quality Index (DLQI) scores of 0/1 (week 100 through week 252) were assessed. Non-responders were patients who met the treatment failure rules. Efficacy endpoints were analyzed using the as-observed methodology (no missing data imputation) for both studies and using non-responder imputation (for patients with any missing data) in VOYAGE 1. Safety outcomes were based on pooled data through week 252. Results: Response rates through week 252 for 199 Asian patients in the guselkumab group in VOYAGE 1 and VOYAGE 2, respectively, were 76.8% and 80.6% (PASI 90), 26.8% and 38.7% (PASI 100), 64.3% and 87.1% (IGA 0/1), and 26.8% and 45.2% (IGA 0). DLQI (0/1) at week 252 was achieved by 52.7% of patients in VOYAGE 1 and 61.3% in VOYAGE 2, while DLQI (0) at week 252 was achieved by 32.7% of patients in VOYAGE 1 and 40.3% in VOYAGE 2. The safety profile was similar to the global population and remained consistent through 5 years. Asian patients were followed for a total of 814 patient-years (PY). Over 85% of the guselkumab-treated patients continued treatment through week 264. The rate of serious adverse events (AEs) at week 252 was 3.07/100 PY. Rates of AEs of interest were low: serious infections, 0.74/100 PY; nonmelanoma skin cancer (NMSC), no patients; malignancies other than NMSC, 0.12/100 PY; and no major adverse cardiovascular events (MACE). Conclusion: These analyses confirm a continuous response over 5 years, indicating that guselkumab shows therapeutic longevity in Asian patients requiring long-term treatment for moderate-to-severe psoriasis. Trial Registration: ClinicalTrials.gov identifiers: VOYAGE 1 [NCT02207231] and VOYAGE 2 [NCT02207244]. Plain Language Summary: Psoriasis—a long-term condition that causes a skin rash with scaly, itchy patches (plaques)—is becoming more prevalent in Asia. To control symptoms of moderate-to-severe psoriasis and achieve a strong improvement in the patient's quality of life, continuous treatment is usually needed. Guselkumab is a medicine that targets specific parts of the immune system to treat moderate-to-severe psoriasis. It is important to understand the long-term benefits of guselkumab in Asian patient populations. Our study analyzed the data from two randomized clinical trials (called VOYAGE 1 and VOYAGE 2) that studied people with moderate-to-severe plaque psoriasis. We examined results for the 199 people from Asia, including Korea and Taiwan, who took part in these studies. Overall, 162 of the 184 (86.6%) people from Asia treated with guselkumab incorporated into these studies continued the treatment for 5 years. Patients treated with guselkumab showed effective clinical responses (improvements measured by clinicians), including high skin clearance, meaning a large reduction in skin surface area affected by psoriasis. On guselkumab, patients also reported improvements in their skin-related health-related quality of life. These improvements and the efficacy of guselkumab were maintained over 5 years of follow-up. The safety results for guselkumab in the Asian subpopulation were similar to those for the global population, showing low rates of serious adverse effects, as expected from this type of medicine. Overall, our study found a favorable benefit–risk profile with continuous guselkumab treatment for 5 years in Asian people with moderate-to-severe psoriasis. This highlights that guselkumab treatment allows long-lasting control of this disease. [ABSTRACT FROM AUTHOR]

The challenge of providing authentic experiences and interactions for fostering oral proficiency and motivation in foreign languages is an opportunity for innovation in educational technology and instructional design. Although several recent innovations have received the attention of scholars, empirical investigation and validation is often lacking, as is the case with voice over instant messaging (VoIM). The goal of this study was to empirically test the effectiveness of VoIM for enhancing students' oral English proficiency and learning motivation. Different types of online discussions were examined--unstructured, structured without the facilitation of English teaching assistants (ETAs) and structured with the facilitation of ETAs. A pre-test and post-test quasi-experimental design was employed to achieve this goal. The participants, 90 students enrolled in three sections of a freshman English course at a large university in Asia, participated in eight VoIM discussions in addition to their regular coursework. The results provide empirical support for the importance of structured discussions and the facilitation of ETAs in improving both oral English proficiency and learning motivation. These findings highlight the role of facilitation in VoIM discussions, and recommend prompt feedback, modelling and encouragement for fostering oral proficiency and learning motivation in foreign language classes. Based on the results of this study, recommendations for future research are provided.

Y chromosome haplogroup O3-M122 is the most prevalent haplogroup in East Asia, and provides an ideal tool for dissecting primary dispersals of the East Asians. Most of the sub-haplogroups of O3-M122 have been sufficiently investigated except for O3a1c-002611, despite its great prevalence and huge population, especially in Han Chinese. In this study, we identified 508 individuals with haplogroup O3a1c-002611 out of 7801 males from 117 East and Southeast Asian populations, typed at two newly discovered downstream Y-SNP markers and ten commonly used Y-STRs. Defined by SNPs IMS-JST002611 (in short, 002611), F11, and F238, three lineages internal to haplogroup O3a1c-002611 have distinct geographical distributions. Furthermore, Y-STR diversity shows a general south-to-north decline, which is consistent with the prehistorically northward migration of the other O3-M122 lineages. The northward migration of haplogroup O3a1c-002611 started about 13 thousand years ago (KYA). The expansions of subclades F11 and F238 in ancient Han Chinese began about 5 and 7 KYA immediately after the separation between the ancestors of the Han Chinese and Tibeto-Burman. [ABSTRACT FROM AUTHOR]

There has been a significant increase in Taiwanese investment overseas since the mid-1980s. However, when Taiwanese investors choose to pursue overseas investment, they do not necessarily register this with the government (specifically, with the Investment Commission at the Ministry of Economic Affairs). Although this is a common phenomenon, there has thus far been a scarcity of in-depth analysis of this trend within the published literature. The official statistics on Taiwanese overseas investment, as provided by the Taiwanese government, differ significantly from those provided by the countries in which the investments take place. We can deduce from this that some businessmen engage in foreign investment without registering it with the government, and as a consequence, suggest that the reasons for such non-registering behavior are worthy of study. This paper adopts theoretical and empirical models to observe unregistered overseas investment behavior patterns and to investigate the reasons influencing the decision to engage in unregistered investment. A questionnaire survey is under-taken to estimate the proportion of unregistered investment, with theoretical and empirical analyses being used to explore the factors behind the decision to adopt non-registering behavior. The results show that the proportion of unregistered investment tends to be higher in South-East Asia and China than in the USA and that complicated administrative procedures have a positive influence on this type of behavior. Furthermore, such behavior can be predetermined by the prospects of higher returns on investment. JEL Classification Code: F21, F23, N75 O17. [ABSTRACT FROM AUTHOR]